FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089028082> ?p ?o ?g. }

• W3089028082 endingPage "914" @default.
• W3089028082 startingPage "914" @default.
• W3089028082 abstract "Praziquantel is an antiparasitic drug indicated for the treatment of the schistosomiasis disease. This drug has very low aqueous solubility, requiring high oral doses for its administration which gives rise to side effects, therapeutic noncompliance and the appearance of resistant forms of the parasite. Clay minerals, like sepiolite and montmorillonite, are innocuous, non-toxic, biocompatible and low-cost excipients. Additionally, clays have high adsorbent properties that allow them to encapsulate drugs in nanometric spaces present in the channels in the case of the sepiolite or between the layers in the case of the montmorillonite. The interactions between the drug and clay minerals are studied experimentally with the strategy for preparing interactions products in organic solvents (ethanol, acetonitrile and dichloromethane) so that the interaction will be more effective and will be enhanced the aqueous solubility of praziquantel. The results showed that in the interaction products, the drug interacted with both clay minerals, which produced the loss of the crystallinity of the drug demonstrated by different techniques. This led to a significant increase in the dissolution rate of the praziquantel in all the interaction products in the simulated gastrointestinal tract media, except for the praziquantel–montmorillonite product prepared in dichloromethane that presented a controlled release in acid medium. Moreover, in vitro cytotoxicity and cell cycle studies were performed in the interaction products prepared with ethanol. The interaction product with sepiolite was biocompatible with the HTC116 line cells, and it did not produce alterations in the cell cycle. However, interaction products with montmorillonite did not produce cell death, but they showed affectation and damage of cells in the cell cycle study at the highest concentration tested (20–100 µM). Therefore, the different organic solvents used are adequate for the improvement of the biopharmaceutical profile of praziquantel. Drug–clay interaction products, specifically with sepiolite, showed very promising results in which new accelerated oral release systems of the praziquantel were obtained." @default.
• W3089028082 created "2020-10-01" @default.
• W3089028082 creator A5005656173 @default.
• W3089028082 creator A5010948488 @default.
• W3089028082 creator A5033042201 @default.
• W3089028082 creator A5056817675 @default.
• W3089028082 creator A5085634976 @default.
• W3089028082 date "2020-09-24" @default.
• W3089028082 modified "2023-10-16" @default.
• W3089028082 title "Praziquantel–Clays as Accelerated Release Systems to Enhance the Low Solubility of the Drug" @default.
• W3089028082 cites W1498305210 @default.
• W3089028082 cites W1513892485 @default.
• W3089028082 cites W1542390160 @default.
• W3089028082 cites W1556575600 @default.
• W3089028082 cites W1976656705 @default.
• W3089028082 cites W1977903767 @default.
• W3089028082 cites W1980535921 @default.
• W3089028082 cites W1986508774 @default.
• W3089028082 cites W1990861050 @default.
• W3089028082 cites W1993816034 @default.
• W3089028082 cites W1993850123 @default.
• W3089028082 cites W1996760500 @default.
• W3089028082 cites W1996912087 @default.
• W3089028082 cites W2003418191 @default.
• W3089028082 cites W2004036804 @default.
• W3089028082 cites W2010777344 @default.
• W3089028082 cites W2011618062 @default.
• W3089028082 cites W2028837618 @default.
• W3089028082 cites W2054253681 @default.
• W3089028082 cites W2056304970 @default.
• W3089028082 cites W2057739013 @default.
• W3089028082 cites W2059148258 @default.
• W3089028082 cites W2064804521 @default.
• W3089028082 cites W2072455063 @default.
• W3089028082 cites W2082002173 @default.
• W3089028082 cites W2092787782 @default.
• W3089028082 cites W2115439624 @default.
• W3089028082 cites W2116649007 @default.
• W3089028082 cites W2132753699 @default.
• W3089028082 cites W2142635246 @default.
• W3089028082 cites W2149143646 @default.
• W3089028082 cites W2170713504 @default.
• W3089028082 cites W2344800598 @default.
• W3089028082 cites W2508274901 @default.
• W3089028082 cites W2594646814 @default.
• W3089028082 cites W2777377683 @default.
• W3089028082 cites W2791893358 @default.
• W3089028082 cites W2892502925 @default.
• W3089028082 cites W2894327334 @default.
• W3089028082 cites W2906001376 @default.
• W3089028082 cites W2911135908 @default.
• W3089028082 cites W2954928410 @default.
• W3089028082 cites W2979820109 @default.
• W3089028082 cites W3046138712 @default.
• W3089028082 cites W4234539946 @default.
• W3089028082 doi "https://doi.org/10.3390/pharmaceutics12100914" @default.
• W3089028082 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7598598" @default.
• W3089028082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32987673" @default.
• W3089028082 hasPublicationYear "2020" @default.
• W3089028082 type Work @default.
• W3089028082 sameAs 3089028082 @default.
• W3089028082 citedByCount "17" @default.
• W3089028082 countsByYear W30890280822020 @default.
• W3089028082 countsByYear W30890280822021 @default.
• W3089028082 countsByYear W30890280822022 @default.
• W3089028082 countsByYear W30890280822023 @default.
• W3089028082 crossrefType "journal-article" @default.
• W3089028082 hasAuthorship W3089028082A5005656173 @default.
• W3089028082 hasAuthorship W3089028082A5010948488 @default.
• W3089028082 hasAuthorship W3089028082A5033042201 @default.
• W3089028082 hasAuthorship W3089028082A5056817675 @default.
• W3089028082 hasAuthorship W3089028082A5085634976 @default.
• W3089028082 hasBestOaLocation W30890280821 @default.
• W3089028082 hasConcept C127413603 @default.
• W3089028082 hasConcept C13965031 @default.
• W3089028082 hasConcept C155574463 @default.
• W3089028082 hasConcept C178790620 @default.
• W3089028082 hasConcept C181389837 @default.
• W3089028082 hasConcept C185592680 @default.
• W3089028082 hasConcept C206139338 @default.
• W3089028082 hasConcept C2777515222 @default.
• W3089028082 hasConcept C2781151301 @default.
• W3089028082 hasConcept C42360764 @default.
• W3089028082 hasConcept C46275449 @default.
• W3089028082 hasConcept C71924100 @default.
• W3089028082 hasConcept C8010536 @default.
• W3089028082 hasConcept C88380143 @default.
• W3089028082 hasConcept C98274493 @default.
• W3089028082 hasConceptScore W3089028082C127413603 @default.
• W3089028082 hasConceptScore W3089028082C13965031 @default.
• W3089028082 hasConceptScore W3089028082C155574463 @default.
• W3089028082 hasConceptScore W3089028082C178790620 @default.
• W3089028082 hasConceptScore W3089028082C181389837 @default.
• W3089028082 hasConceptScore W3089028082C185592680 @default.
• W3089028082 hasConceptScore W3089028082C206139338 @default.
• W3089028082 hasConceptScore W3089028082C2777515222 @default.
• W3089028082 hasConceptScore W3089028082C2781151301 @default.
• W3089028082 hasConceptScore W3089028082C42360764 @default.

• next